{"id":"dehydroepiandrosterone-bay86-5314","brandName":"Dehydroepiandrosterone, BAY86-5314","genericName":"Dehydroepiandrosterone, BAY86-5314","companyId":"bayer","companyName":"Bayer","phase":"phase_2","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Dehydroepiandrosterone (DHEA) is being evaluated by Bayer as an adjunct therapy to oral contraceptives for women with reduced libido. Phase 2 trials have been completed, showing potential efficacy and safety. The drug is not yet FDA-approved but has shown promise in addressing a significant unmet need.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Dehydroepiandrosterone is a precursor to androgen and estrogen hormones, and its administration has been explored for various conditions, including fatigue, depression, and osteoporosis. However, its exact mechanism of action is not fully understood.","oneSentence":"Dehydroepiandrosterone is a naturally occurring steroid hormone that has been investigated for its potential therapeutic effects.","_ai_confidence":"medium"},"administration":{},"safety":{"commonSideEffects":[{"rate":"null","effect":"Hirsutism"},{"rate":"null","effect":"Acne"},{"rate":"null","effect":"Hypertension"}]},"trials":[],"indications":{"approved":[{"name":"Fatigue"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}